United Therapeutics Gets FDA Clearance for Treprostinil SMI Trial in PH-COPD

• FDA cleared United Therapeutics to begin the phase 2 SUMMIT trial of treprostinil SMI in PH-COPD.
• The 16-week study will evaluate safety and tolerability in approximately 40 patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261019217134) on October 19, 2026, and is solely responsible for the information contained therein.